Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development will present at the upcoming Jefferies Healthcare Conference being held on June 8-10, 2022, in New York, NY.
HOUSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development will present at the upcoming Jefferies Healthcare Conference being held on June 8-10, 2022, in New York, NY.
Details for the presentation are below:
Event: Jefferies 2022 Global Healthcare Conference
Date: Friday, June 10, 2022
Time: 9:00-9:25 am ET
Location: New York Marriott Marquis
Room: Track 6
A live webcast of the presentation will be accessible on the Company’s website in the Investors section under Events & Presentations at www.alaunos.com or by using the link here. A replay of the webcast will be available on the Alaunos website for approximately 90 days following the presentation.
About Alaunos Therapeutics
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer technology and its TCR library targeting shared tumor-specific hotspot mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has clinical and strategic collaborations with The University of Texas MD Anderson Cancer Center and the National Cancer Institute. For more information, please visit www.alaunos.com.
Investor Relations Contact: Alex Lobo Stern Investor Relations Alex.lobo@sternir.com
